Financials

News Ideas Technicals

ALHYG fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Hybrigenics SA operates as a biopharmaceutical company which engages in the research and development of targets and therapies for the treatment of proliferative diseases. It develops inecalcitol for the treatment of prostate cancer, acute and chronic lymphocytic leukemia, and acute and chronic myeloid leukemia. The company was founded by Arthur Donny Strosberg on December 29, 1997 and is headquartered in Paris, France.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

ALHYG does not pay dividends

The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company